Sequenom announces European licensing agreement with GATC subsidiary LifeCodexx

San Diego, California / Constance, Germany – Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced it has partnered with LifeCodexx AG, a company focused on the development of clinically proven Next Generation Molecular Diagnostics for the commercialization of prenatal laboratory testing services in Europe.

Read more

GATC Biotech and LifeCodexx develop a diagnostic test for early detection of preeclampsia

Constance, Germany – Preeclampsia is a hypertensive disorder of the mother during pregnancy. It is among the leading causes of death of mother and unborn child and occurs in approximately two to five percent of all pregnancies in Germany. Early detection is critical and improves the prognosis for the further course of the pregnancy.

On the basis of next generation sequencing technologies GATC Biotech and LifeCodexx will develop a human genetic diagnostic test that will allow the detection of cell-free fetal DNA as an important early marker.

Read more

Successful pilot study for non-invasive prenatal diagnostic test to determine trisomy 21

Constance, Germany– At the moment, the only reliable way of diagnosing chromosomal irregularities during pregnancy is to use invasive prenatal methods. This causes miscarriage in about one per cent of these risky surgical procedures.

Scientists from the Center for Prenatal Diagnosis and Human Genetics, Kudamm-199, in Berlin have been working with scientists from GATC Biotech AG and LifeCodexx AG to develop a non-invasive diagnostic test based on Next Generation Sequencing which reliably detects a fetal trisomy 21 (Down syndrome).

Read more